Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Season 2009/2010. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects.

Next Previous
Trial Profile

Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Season 2009/2010. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Solvay Pharmaceuticals

Most Recent Events

  • 15 Mar 2012 This trial is recruting in Germany as reported by European Clinical Trials Database.
  • 15 Mar 2012 Actual initiation date changed from Jun 2009 to May 2009 as reported by European Clinical Trials Database.
  • 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top